Trial Profile
The Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, Non-Cirrhotic, HCV GT4-Infected Patients: A Single-Center, Single-Arm, Open-Label, Phase III Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ELEGANT-4
- 18 Nov 2020 Status changed from not yet recruiting to completed.
- 12 Jul 2018 New trial record